288 related articles for article (PubMed ID: 19351365)
41. Ameloblastomas: a regional Latin-American multicentric study.
Ledesma-Montes C; Mosqueda-Taylor A; Carlos-Bregni R; de León ER; Palma-Guzmán JM; Páez-Valencia C; Meneses-García A
Oral Dis; 2007 May; 13(3):303-7. PubMed ID: 17448213
[TBL] [Abstract][Full Text] [Related]
42. Tumor-associated macrophages and angiogenesis: a statistical correlation that could reflect a critical relationship in ameloblastoma.
Guzmán-Medrano R; Arreola-Rosales RL; Shibayama M; Silva-Olivares DA; Bologna-Molina R; Rodríguez MA
Pathol Res Pract; 2012 Nov; 208(11):672-6. PubMed ID: 23041027
[TBL] [Abstract][Full Text] [Related]
43. Histochemistry of Ki-67 antigen in ameloblastomas.
Nagao Y; Wato M; Tanaka A
J Osaka Dent Univ; 1999 Oct; 33(2):53-7. PubMed ID: 10863475
[TBL] [Abstract][Full Text] [Related]
44. Comparison of angiogenesis in keratocystic odontogenic tumours, dentigerous cysts and ameloblastomas.
Alaeddini M; Salah S; Dehghan F; Eshghyar N; Etemad-Moghadam S
Oral Dis; 2009 Sep; 15(6):422-7. PubMed ID: 19413675
[TBL] [Abstract][Full Text] [Related]
45. Nucleolar organizer regions in selected odontogenic lesions.
Eslami B; Yaghmaei M; Firoozi M; Saffar AS
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Feb; 95(2):187-92. PubMed ID: 12582359
[TBL] [Abstract][Full Text] [Related]
46. Some current concepts on the pathology of ameloblastomas.
Gardner DG
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 1996 Dec; 82(6):660-9. PubMed ID: 8974139
[TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical expression of MMP-9, TIMP-2, E-cadherin and vimentin in ameloblastomas and their implication in the local aggressive behavior of these tumors.
Florescu A; Mărgăritescu C; Simionescu CE; Stepan A
Rom J Morphol Embryol; 2012; 53(4):975-84. PubMed ID: 23303021
[TBL] [Abstract][Full Text] [Related]
48. Alpha-smooth muscle actin within epithelial islands is predictive of ameloblastic carcinoma.
Bello IO; Alanen K; Slootweg PJ; Salo T
Oral Oncol; 2009 Sep; 45(9):760-5. PubMed ID: 19150605
[TBL] [Abstract][Full Text] [Related]
49. Cystic ameloblastoma--behavior and treatment of 21 cases.
Rosenstein T; Pogrel MA; Smith RA; Regezi JA
J Oral Maxillofac Surg; 2001 Nov; 59(11):1311-6; discussion 1316-8. PubMed ID: 11688034
[TBL] [Abstract][Full Text] [Related]
50. Gene mutation analysis and immunohistochemical study of beta-catenin in odontogenic tumors.
Miyake T; Tanaka Y; Kato K; Tanaka M; Sato Y; Ijiri R; Inayama Y; Ito Y; Aoki S; Kawabe R; Tohnai I
Pathol Int; 2006 Dec; 56(12):732-7. PubMed ID: 17096730
[TBL] [Abstract][Full Text] [Related]
51. Expression of proteoglycans in two types of ameloblastoma: novel Immunohistochemical findings.
Gómez-Herrera Z; Molina-Frechero N; Damián-Matsumura P; González-González R; Farfán-Morales JE; Bologna-Molina R
J Biol Regul Homeost Agents; 2018; 32(3):479-487. PubMed ID: 29921372
[TBL] [Abstract][Full Text] [Related]
52. Immunoexpression of Ki-67, MCM2, and MCM3 in Ameloblastoma and Ameloblastic Carcinoma and Their Correlations with Clinical and Histopathological Patterns.
Carreón-Burciaga RG; González-González R; Molina-Frechero N; Bologna-Molina R
Dis Markers; 2015; 2015():683087. PubMed ID: 26823641
[TBL] [Abstract][Full Text] [Related]
53. Differential expression profiles between α-dystroglycan and integrin β1 in ameloblastoma: two possible perlecan signalling pathways for cellular growth and differentiation.
Ida-Yonemochi H; Ahsan MS; Saku T
Histopathology; 2011 Jan; 58(2):234-45. PubMed ID: 21255062
[TBL] [Abstract][Full Text] [Related]
54. The evaluation of p16 and Ki67 immunoexpression in ameloblastomas.
Olimid DA; Florescu AM; Cernea D; Georgescu CC; Mărgăritescu C; Simionescu CE; Stepan AE
Rom J Morphol Embryol; 2014; 55(2):363-7. PubMed ID: 24969987
[TBL] [Abstract][Full Text] [Related]
55. Syndecan-1 and Wingless-type protein-1 in human ameloblastomas.
Leocata P; Villari D; Fazzari C; Lentini M; Fortunato C; Nicòtina PA
J Oral Pathol Med; 2007 Aug; 36(7):394-9. PubMed ID: 17617831
[TBL] [Abstract][Full Text] [Related]
56. Immunoexpression of transforming growth factor beta in desmoplastic ameloblastoma.
Takata T; Miyauchi M; Ogawa I; Kudo Y; Takekoshi T; Zhao M; Sato S; Nikai H; Komiyama K
Virchows Arch; 2000 Apr; 436(4):319-23. PubMed ID: 10834533
[TBL] [Abstract][Full Text] [Related]
57. Expression of transforming growth factor beta1 in ameloblastomas.
Iezzi G; Piattelli A; Rubini C; Artese L; Goteri G; Perrotti V; Carinci F
J Craniofac Surg; 2008 Nov; 19(6):1618-21. PubMed ID: 19098564
[TBL] [Abstract][Full Text] [Related]
58. Apoptosis-related factors (TRAIL, DR4, DR5, DcR1, DcR2, apoptotic cells) and proliferative activity in ameloblastomas.
Rizzardi C; Leocata P; Ventura L; Zweyer M; Brollo A; Schneider M; Melato M
Anticancer Res; 2009 Apr; 29(4):1137-42. PubMed ID: 19414356
[TBL] [Abstract][Full Text] [Related]
59. Calretinin expression in ameloblastomas.
Altini M; Coleman H; Doglioni C; Favia G; Maiorano E
Histopathology; 2000 Jul; 37(1):27-32. PubMed ID: 10931215
[TBL] [Abstract][Full Text] [Related]
60. Immunolocalization of podoplanin in benign odontogenic tumours with and without ectomesenchyme.
Caetano Ados S; Tjioe KC; Faustino SE; Hanemann JA; Belone Ade F; Soares CT; Oliveira DT
Arch Oral Biol; 2013 Apr; 58(4):408-15. PubMed ID: 22763018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
